Stocks · News reference
Chardan Capital analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ:HIND) with a Buy rating and announces Price Target of $3.5.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s
Filed: 2026-08-28 AccNo: 0001213900-26-095093 Size: 267 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out